Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, One Center, Phase II Study of Erlotinib as Neoadjuvant Treatment in Patients With Endobronchial Ultrasound(EBUS) Confirmed Stage IIIA N2 Non-small Cell Lung Cancer(NSCLC) With Activating Epithelial Growth Factor Receptor (EGFR) Mutation in Exon 19 or 21.

Next Previous
Trial Profile

A Single Arm, One Center, Phase II Study of Erlotinib as Neoadjuvant Treatment in Patients With Endobronchial Ultrasound(EBUS) Confirmed Stage IIIA N2 Non-small Cell Lung Cancer(NSCLC) With Activating Epithelial Growth Factor Receptor (EGFR) Mutation in Exon 19 or 21.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ESTERN

Most Recent Events

  • 01 Jan 2021 Results (n=29) of a study assessing safety and feasibility of pulmonary resection after EGFR-TKI induction from patients enrolled in this trial published in the Annals of Thoracic Surgery
  • 29 Dec 2019 Results comparing the clinical benefits of erlotinib versus chemotherapy as neoadjuvant treatment in Chinese patients with stage IIIA NSCLC published in the Journal of International Medical Research
  • 07 Mar 2012 Planned End Date changed from 1 Dec 2013 to 1 Jan 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top